Exploring the Diverse Immune and Genetic Landscape of Psoriatic Arthritis

Exploring the Diverse Immune and Genetic Landscape of Psoriatic Arthritis

Psoriatic arthritis (PsA) is characterized by delays in diagnosis and modest effect of treatment in terms of joint response. An understanding of molecular pathomechanisms may aid in developing diagnostic and prognostic models. Genetic susceptibility (e.g., HLA class I genes, IL-23-related genes) can...

Full description

Bibliographic Details
Main Author:	Bogdan Batko
Format:	Article
Language:	English
Published:	MDPI AG 2021-12-01
Series:	Journal of Clinical Medicine
Subjects:	psoriatic arthritis inflammation interleukin-17 interleukin-23 pathomechanism modulation
Online Access:	https://www.mdpi.com/2077-0383/10/24/5926

Similar Items

Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints
by: Marie-Astrid Boutet, et al.
Published: (2018-02-01)

Prospects for the use of monoclonal antibodies to interleukin 23 Gusеlkumab in psoriatic arthritis: New data
by: E. L. Nasonov, et al.
Published: (2022-03-01)

The Role of the IL-23/IL-17 Pathway in the Pathogenesis of Spondyloarthritis
by: Hiroyuki Tsukazaki, et al.
Published: (2020-09-01)

Efficacy and safety of netakimab in patients with psoriatic arthritis: results of the phase III PATERA clinical study
by: T. V. Korotaeva, et al.
Published: (2020-11-01)

Distinct In Vitro T-Helper 17 Differentiation Capacity of Peripheral Naive T Cells in Rheumatoid and Psoriatic Arthritis
by: Eszter Baricza, et al.
Published: (2018-04-01)

An Overview of Bimekizumab for the Treatment of Psoriatic Arthritis: The Evidence so Far
by: G Oliveira D, et al.
Published: (2021-03-01)

Efficacy of netakimab in key psoriatic arthritis domains: 54-week results from the phase III BCD-085-8/PATERA study
by: T. V. Korotaeva, et al.
Published: (2021-03-01)

Drug survival of biologic agents in patients with psoriatic arthritis from a medical center in southern Taiwan
by: Sebastian Yu, et al.
Published: (2022-01-01)

Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials
by: Joseph F. Merola, et al.
Published: (2024-12-01)

Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis
by: Alexis Ogdie, et al.
Published: (2023-05-01)

Inflammatory Cytokines in Psoriatic Arthritis: Understanding Pathogenesis and Implications for Treatment
by: Bong-Woo Lee, et al.
Published: (2023-07-01)

IL-23 Inhibitors to treat psoriatic arthritis: A systematic review & meta-analysis of randomized controlled trials
by: Ahmed Safi Vahidy, et al.
Published: (2023-12-01)

Use of the interleukin-17A inhibitor secukinumab in psoriatic arthritis: a subanalysis of the Russian population in the international randomized clinical trials FUTURE 1 and FUTURE 2
by: T. V. Korotaeva, et al.
Published: (2017-04-01)

Palmoplantar pustulosis with psoriatic arthritis ineffective to interleukin-17 inhibitors: two patients successfully treated with upadacitinib
by: Zeng-Yun-Ou Zhang, et al.
Published: (2023-12-01)

Impact of Adalimumab Treatment on Interleukin-17 and Interleukin-17 Receptor Expression in Skin and Synovium of Psoriatic Arthritis Patients with Mild Psoriasis
by: Janne W. Bolt, et al.
Published: (2022-01-01)

Ixekizumab for Psoriatic Arthritis: Safety, Efficacy, and Patient Selection
by: Miller J, et al.
Published: (2021-12-01)

Maternal Interleukin-17 and disease activity influence pregnancy outcomes in women with psoriatic arthritis and ankylosing spondylitis
by: Ehab F. Girbash, et al.
Published: (2023-01-01)

The Role of Interleukin-17 in Juvenile Idiopathic Arthritis: From Pathogenesis to Treatment
by: Marino Paroli, et al.
Published: (2022-10-01)

ASSOCIATION BETWEEN POLYMORPHIC MARKERS OF THE IL4 (с-590Т) AND IL10 (с-597А) GENES AND PSORIATIC ARTHRITIS
by: M. V. Smolnikova, et al.
Published: (2012-05-01)

Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies
by: Guillermo Sánchez-Rodríguez, et al.
Published: (2023-06-01)

Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study
by: Ippei Miyagawa, et al.
Published: (2022-04-01)

PROSPECTS FOR USING INTERLEUKIN-17 INHIBITORS, A NEW CLASS OF DRUGS FOR TARGETED THERAPY OF PSORIATIC ARTHRITIS
by: T. V. Korotaeva
Published: (2016-07-01)

Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1)
by: Hideto Kameda, et al.
Published: (2023-10-01)

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)
by: Peter Nash, et al.
Published: (2018-03-01)

Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies
by: Laura C. Coates, et al.
Published: (2019-12-01)

IL‐23/IL‐17 immune axis mediates the imiquimod‐induced psoriatic inflammation by activating ACT1/TRAF6/TAK1/NF‐κB pathway in macrophages and keratinocytes
by: Wen‐Cheng Chen, et al.
Published: (2023-08-01)

NEW POSSIBILITIES OF PHARMACOTHERAPY FOR IMMUNOINFLAMMATORY RHEUMATIC DISEASES: A FOCUS ON INHIBITORS OF INTERLEUKIN-17
by: E. L. Nasonov
Published: (2017-03-01)

Levels of IL-23/IL-17 Axis in Plasma and Gingival Tissue of Periodontitis Patients According to the New Classification
by: Ruth Rodríguez-Montaño, et al.
Published: (2022-08-01)

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study
by: L. C. Coates, et al.
Published: (2018-12-01)

Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis
by: Proton Rahman, et al.
Published: (2021-07-01)

Interleukin 17A inhibitor secukinumab in the treatment of patients with psoriatic arthritis
by: N. A. Shostak, et al.
Published: (2022-10-01)

Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study
by: Laure Gossec, et al.
Published: (2023-06-01)

Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review
by: Pinter A, et al.
Published: (2019-07-01)

Patient-Centered Care in Psoriatic Arthritis—A Perspective on Inflammation, Disease Activity, and Psychosocial Factors
by: Bogdan Batko
Published: (2020-09-01)

IS PSORIATIC ARTHRITIS REALLY PSORIATIC?
by: Sh. F. Erdes
Published: (2014-12-01)

Fatigue – an underestimated symptom in psoriatic arthritis
by: Magdalena Krajewska-Włodarczyk, et al.
Published: (2017-07-01)

Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation—data from the prospective IVEPSA study
by: Eleni Kampylafka, et al.
Published: (2019-07-01)

A case-control study on immunologic markers of patients with vitiligo
by: Barbara Nieradko-Iwanicka, et al.
Published: (2022-12-01)

Psoriatic arthritis: genetics and pathogenesis
by: A. Mathieu, et al.
Published: (2012-06-01)

Targeted Therapies in Psoriatic Arthritis—An Update
by: Sonia Sundanum, et al.
Published: (2023-03-01)